Clinical Trials List
2024-01-01 - 2030-06-30
Phase III
Recruiting4
ICD-10C76.0
Malignant neoplasm of head, face and neck
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9195.0
Malignant neoplasm of other and ill-defined sites of head, face and neck
-
Trial Applicant
GlaxoSmithKline
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 陳珈妤 無
- Ming-Yu Lien 無
- Yu-Min Liao 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王駿瑋 無
- 黃彥霖 無
- Hsiang-Fong Kao 無
- 廖斌志 無
- YA-FANG CHEN 無
- RUEY-LONG HONG 無
- 楊明翰 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
25 participants
-
Global
864 participants
